Clinical trials
Pancreatic Adenocarcinoma Advanced or Metastatic clinical trials
Below are recruiting pancreatic adenocarcinoma advanced or metastatic clinical trials, each written for real people, not researchers. We’re tracking 3,887 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06112990RecruitingPhase 3
Creatine and exercise to keep muscles strong in prostate cancer
This trial tests if taking creatine plus doing resistance exercises at home can help men with prostate cancer maintain muscle mass and slow cancer growth. You would take creatine or a placebo for 52 weeks and do simple strength exercises twice a week.
Salt Lake City, UtahAges 18 years+ - NCT06114004RecruitingPhase 2
Selinexor plus gemcitabine for advanced soft-tissue sarcoma
This trial tests a combination of two drugs, selinexor and gemcitabine, for people with a type of soft-tissue sarcoma (leiomyosarcoma or malignant peripheral nerve sheath tumor) that has spread or cannot be surgically removed and has gotten worse despite at least one prior treatment. The goal is to see if this combination can help shrink or slow the cancer.
Santa Cruz de Tenerife, Canary IslandsAges 18–80 - NCT06116786RecruitingPhase 1
Experimental drug JNJ-86974680 for advanced lung cancer
This study tests an experimental drug called JNJ-86974680 for people with advanced non-small cell lung cancer. It looks at how well the drug works, whether you have a gene change or not, and what treatments you've already had.
Newnan, GeorgiaAges 18 years+ - NCT06121557RecruitingPhase 1
Immune cells from lymph nodes for advanced HER2-negative breast cancer
This trial tests a treatment using your own immune cells taken from lymph nodes near the tumor. The cells are grown in a lab and given back to you to fight cancer, along with another drug chosen by your doctor.
Guangzhou, GuangdongAges 18–70 - NCT06123338RecruitingPhase 2
Pembrolizumab plus chemo and trastuzumab for HER2+ stomach cancer
This trial tests adding pembrolizumab to standard trastuzumab and chemotherapy for people with HER2-positive stomach or esophageal cancer that can be fully removed with surgery. The goal is to see if this combination improves outcomes before and after surgery.
Boston, MassachusettsAges 18 years+ - NCT06126406RecruitingPhase 1
CEA-targeting CAR-T cell therapy for advanced solid tumors
This trial tests a new immune cell therapy (CAR-T) designed to attack cancer cells that make a protein called CEA. It may be an option for people with advanced colorectal, esophageal, gastric, or pancreatic cancer who have already tried at least two standard treatments.
Wuhu, AnhuiAges 18 years+ - NCT06127303RecruitingPhase 2
Toripalimab plus cryoablation for lung cancer with limited progression
This trial tests a combination of an immunotherapy drug (toripalimab) and a freezing treatment (cryoablation) for people with advanced non-small cell lung cancer that has started to grow again in only a few spots after initial treatment. It aims to see if this approach can help control the cancer without switching to a completely new therapy.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06130995RecruitingPhase 1
Relugolix and enzalutamide for high-risk prostate cancer
This trial tests a combination of two oral drugs, relugolix and enzalutamide, in men with high-risk prostate cancer that hasn't spread to distant parts of the body. The goal is to see if this treatment can help control the cancer before or alongside local therapies like surgery or radiation.
Oklahoma City, OklahomaAges 18 years+ - NCT06135714RecruitingPhase 3
Targeting limited breast cancer spread with focused therapy
This trial tests whether treating just the few spots where breast cancer has spread (called oligometastases) with radiation or surgery can help control the disease. It is for people whose cancer has spread to 3 or fewer places, each small in size, and who are healthy enough for local treatments.
Tokyo, TokyoAges 18–80 - NCT06136884RecruitingPhase 1
Study of AO-252 for advanced solid tumors with or without brain metastases
This trial tests an experimental oral pill (AO-252) that targets a protein called TACC3 in advanced solid tumors, including those that have spread to the brain. It is for people whose cancer has a specific genetic change (TP53 mutation) or who have prostate cancer, and who have already tried other treatments.
Detroit, MichiganAges 18 years+ - NCT06141226RecruitingPhase 2
New drug combo for immunotherapy-resistant lung cancer
This trial tests a combination of an immunotherapy drug (TQB2450), a targeted therapy (anlotinib), and chemotherapy for people with advanced non-small cell lung cancer whose cancer stopped responding to prior immunotherapy. It aims to find a new option when the first treatment didn't work anymore.
Huizhou, GuangdongAges 18–75 - NCT06149130RecruitingPhase 2
Testing adebrelimab, dalpiciclib, and hormone therapy for advanced breast cancer
This trial tests a combination of a new immunotherapy drug (adebrelimab) with a targeted pill (dalpiciclib) and standard hormone therapy for women with advanced hormone receptor positive, HER2 negative breast cancer. It may help patients who have not yet had certain prior treatments, aiming to slow the cancer's growth.
Wuhan, HubeiAges 18–75 - NCT06155396RecruitingPhase 2
Targeted drug combo for advanced cervical cancer
This trial tests a combination of two drugs: an antibody-drug conjugate (RC48-ADC) that targets HER2 on cancer cells, plus an immunotherapy (Zimberelimab) that helps your immune system attack the cancer. It is for people with advanced cervical cancer whose prior platinum-based chemotherapy has stopped working.
Bengbu, AnhuiAges 18 years+ - NCT06158919Recruiting
Immunotherapy Plus Targeted Therapy and Chemo for Stomach Cancer
This trial tests a combination of immunotherapy (PD-1 inhibitor), a targeted drug (fruquintinib), and chemotherapy as a first treatment for advanced stomach or gastroesophageal junction cancer that is HER2-negative. It aims to see if this combination can shrink tumors and help people live longer.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06160596Recruiting
Understanding long-term cancer survival in hard-to-treat tumors
This study looks at why some people with hard-to-treat cancers live much longer than expected. It collects tumor samples to search for clues that might help future patients.
VillejuifAges 18 years+ - NCT06161974RecruitingPhase 2
Olutasidenib and temozolomide for IDH1-mutant high-grade glioma
This trial tests a combination of two oral medications, olutasidenib and temozolomide, for people with a specific type of aggressive brain tumor (high-grade glioma) that has an IDH1 mutation. The goal is to see if this combination can help control the tumor after standard treatment like radiation.
Aurora, ColoradoAges 12–39 - NCT06165302Recruiting
Exercise study for men with advanced prostate cancer
This trial tests whether a structured exercise program can help men with metastatic prostate cancer who are on hormone therapy. It looks at changes in cancer cells and overall well-being.
Baltimore, MarylandAges 18–80 - NCT06170788RecruitingPhase 3
New Two-Drug Immunotherapy Combo vs. Standard Immunotherapy for Advanced Lung Cancer
This study compares a new combination of two immunotherapy drugs (sacituzumab tirumotecan plus pembrolizumab) versus pembrolizumab alone for people with advanced non-small cell lung cancer that has a high PD-L1 level (≥50%) and has not been treated yet. The goal is to see if the combination works better than the standard single immunotherapy.
Phoenix, ArizonaAges 18 years+ - NCT06171139Recruiting
Genetic counseling tool for Black men with prostate cancer
This study tests a new tool to help Black or African American men with prostate cancer understand genetic testing options. The goal is to improve counseling and decision-making about tumor genetic testing.
San Francisco, CaliforniaAges 18 years+ - NCT06176885RecruitingPhase 2
Immunotherapy plus chemo and targeted therapy for MSS colorectal cancer
This trial tests adding immunotherapy to standard chemotherapy and targeted therapy for people with metastatic colorectal cancer that is MSS (microsatellite stable) and cannot be removed with surgery. It aims to see if this combination helps shrink tumors and improve outcomes.
Jinhua, ZhejiangAges 18–75 - NCT06177015RecruitingPhase 3
Darolutamide with chemo for metastatic prostate cancer
This trial tests a new way of using darolutamide (a hormone therapy) together with standard chemotherapy (docetaxel) and hormone therapy (ADT) for men with prostate cancer that has spread. The goal is to see if taking darolutamide on an intermittent schedule works as well as continuous treatment.
Nanjing, JiangsuAges 40–80 - NCT06184698RecruitingPhase 2
Liposomal irinotecan, chemotherapy, and bevacizumab for advanced colorectal cancer
This trial tests a combination of liposomal irinotecan, two chemotherapy drugs (leucovorin and 5-fluorouracil), and bevacizumab as a second-line treatment for people with colorectal cancer that has spread and cannot be removed by surgery.
Shijiazhuang, HebeiAges 18–75 - NCT06189209RecruitingPhase 2
Tenalisib for metastatic triple-negative breast cancer
This trial tests a drug called Tenalisib in people with metastatic triple-negative breast cancer who have already tried 1 to 3 chemotherapy treatments. It aims to see if Tenalisib can help shrink tumors and improve outcomes.
Vijayawada, Andhra PradeshAges 18 years+ - NCT06190275Recruiting
Immune cell therapy for advanced head and neck cancer
This trial tests a new immune cell therapy (GT201) combined with a PD-1 inhibitor for advanced head and neck cancer. It aims to see if your own immune cells, collected from your tumor, can be boosted to fight the cancer.
Shanghai, Shanghai MunicipalityAges 18–70
Hear when a new Pancreatic Adenocarcinoma Advanced or Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pancreatic adenocarcinoma advanced or metastatic?
- Yes. Clin2 currently lists 3,887 recruiting pancreatic adenocarcinoma advanced or metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pancreatic adenocarcinoma advanced or metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pancreatic adenocarcinoma advanced or metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Pancreatic Adenocarcinoma
- Locally Advanced Pancreatic Adenocarcinoma
- Metastatic Pancreatic Ductal Adenocarcinoma
- Locally Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (PDAC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.